recovery

Pramipexole (SND 919) is a selective dopamine receptor agonist used in the therapy of Parkinson disease. Pramipexole therapy is associated with a low rate of transient serum enzyme elevations during treatment but has not been implicated in cases of clinically apparent acute liver injury.

Pramipexole dihydrochloride hydrate (Mirapex) is the hydrochloride salt of pramipexole, a benzothiazole derivative. As a nonergot dopamine agonist, pramipexole binds to D2 and D3 dopamine receptors in the striatum and substantia nigra of the brain.

BI-9627 is a selective and potent sodium hydrogen exchange isomer 1 (NHE1) inhibitor.BI-9627 partially reverses the effects of DMA with IC50 values of 6 and 31 nM in the intracellular pH recovery (pHi) and human platelet lysis assays.BI-9627 is often used as a negative control for BI-0054, which can be used for the study of ischemia-reperfusion injury in isolated hearts. BI-9627 is often used as a negative control for BI-0054 and can be used to study ischemia-reperfusion injury in isolated hearts.

NUCC-390, a novel small-molecule CXCR4 receptor agonist, selectively induces CXCR4 receptor internalization while acting antagonistically to AMD3100. This compound facilitates nerve functional recovery following neurodegeneration in vivo.

Stemazole is a novel small molecule human stem/progenitor cell proliferation activator that promotes the survival of human embryonic stem cells and maintains stemness, and promotes the survival of oligodendrocyte precursor cells in vitro. Stemazole significantly increased cell survival and clone formation in a dose-dependent manner, reduced apoptosis, and promoted recovery of motor dysfunction and myelin repair. Stemazole can be used as a therapeutic agent in demyelinating disorders, promoting OPC survival in vitro and regeneration in vivo.

CM-352 is a metalloproteinase inhibitor that reduces brain damage and improves functional recovery in rat models of cerebral hemorrhage.

sn-Glycero-3-phosphocholine (Choline glycerophosphate) is a natural choline compound found in the brain and in milk. It is also a parasympathomimetic acetylcholine precursor which may have a potential for the treatment of Alzheimer's disease and dementia. sn-Glycero-3-phosphocholine rapidly delivers choline to the brain across the blood–brain barrier and is a biosynthetic precursor of the acetylcholine neurotransmitter. It is a non-prescription drug in most countries due to its Generally Recognised As Safe (GRAS) status [1]. Studies have investigated its efficacy for cognitive disorders including stroke and Alzheimer's disease. An Italian multicentre clinical trial on 2, 044 patients suffering from recent stroke were supplied Glycerylphosphorylcholine in doses of 1, 000 mg/day for 28 days and 400 mg three times per day for the five ensuing months. The trial confirmed the therapeutic role of alpha-GPC on the cognitive recovery of patients based on four measurement scales, three of which reached statistical significance [2].

Produced in the gut microflora as one of the three main metabolites formed from the catechin diet. Its use in the production of glycol benzoates for the application of plasticizer in adhesive formulations is increasing. It is also used in the manufacture

Isoquinoline, 5-iodo- is a potent and selective inhibitor of SARM1(IC50 = 75 nM) by preventing axonal degeneration and by allowing functional recovery of a metastable pool of damaged, but viable, axons.

BMS-199264 hydrochloride is the salt form of BMS-199264.BMS-199264 is a potent and selective inhibitor of mitochondrial F1F0 ATP hydrolase with an IC50=0.5 μM.BMS-199264 is able to inhibit the decline of ATP during myocardial ischemia, reduce myocardial necrosis, and enhance the recovery of myocardial contractile function after reperfusion.

Levocarnitine propionate (L-Propionylcarnitine) is a propionyl-coenzyme A (Pro-CoA) derivative with anti-ischemic effects and high affinity for muscle L-carnitine transferase. Levocarnitine propionate enhances substrate oxidation and mitochondrial respiration in the heart of diabetic rats, reduces gastric ulcer area, induces mucosal recovery, and can be used to study acute respiratory distress syndrome and chronic gastric ulcers in Alzheimer's disease.

Nrf2 activator 19 is a compound capable of crossing the blood-brain barrier and acts as an NRF2/HO-1 activator, offering potent antioxidant and neuroprotective effects. It effectively reduces brain damage and minimizes the accumulation of Reactive Oxygen Species (ROS). Additionally, Nrf2 activator 19 inhibits neuronal apoptosis, aiding in the recovery of neural function and motor skills. It has demonstrated significant potential in ischemic stroke research.

JNK-IN-24 is a JNK inhibitor and an anti-metastatic cancer agent. It reduces the expression of JNK and MMP1 in cancer tissues induced by Scrib knockdown. JNK-IN-24 aids in the recovery of the ScribRNAi tumor disc phenotype and is applicable for studying various epithelial-derived cancers.

Glycerophosphoinositol 4,5-diphosphate (GroPI(4,5)P2) trisodium is an analog of InsP3 with slow metabolism. It has an EC50 of 1.228 μM for inducing calcium release and a degradation time constant of 13 seconds. This compound is useful for studying the impact of InsP3 degradation on calcium signal recovery.

CEP03 enhances EC/EPC proliferation, tubelike formation, and wound-healing efficiency, leading to promote angiogenesis and significantly improve blood flow perfusion recovery in the ischemic hind limbs of mice.

Kv7.2/Kv7.3 activator-3 (GRT-X) is an orally active activator of Kv7.2/Kv7.3 channels and the TSPO. It activates Kv7.2/Kv7.3, Kv7.4, and Kv7.5 with EC50 values of 0.37, 2.06, and 0.75 μM, respectively, and binds to TSPO with Ki values of 0.07 μM (rat membrane) and 4.60 μM (human U-118 MG cells). This compound protects motor neurons from degeneration caused by exposure to astrocyte-conditioned media from mice and humans with amyotrophic lateral sclerosis/frontotemporal dementia. Additionally, Kv7.2/Kv7.3 activator-3 stimulates axonal growth in dorsal root ganglia through TSPO and Kv7.2/3 activation and exhibits anticonvulsant effects in epilepsy models. It alleviates hyperalgesia in diabetic neuropathy patients, enhances the survival and regeneration of neurons after cervical neuropathy in rats, and accelerates the recovery of normal function in sensory and motor neurons.

EYE-002 is an RPE65 inhibitor with an IC50 of 69 nM. It enhances the recovery of dark-adapted electroretinogram (ERG) a-/b-wave amplitudes in mice. EYE-002 regulates the visual cycle in mice by reducing 11-cisretinal (11cRAL) synthesis and increasing all-trans-retinyl esters (atREs). It offers protective effects against light-induced retinal damage in mice. EYE-002 is valuable for research on retinal disorders related to the visual cycle, such as Stargardt disease type 1 (STGD1).

GPI-3000 is an NMDA receptor antagonist with potential neuroprotective properties. It may enhance recovery from metabolic damage and has applications in research on metabolic and neurological disorders.

BI-9740 is an orally active, selective inhibitor of cathepsin C (CatC), displaying an IC50 of 0.6 nM in mice and 2.6 nM in rats. It inhibits the production of active neutrophil elastase and also reduces neutrophil elastase and cathepsin G activity in rat bone marrow, thereby alleviating pathological damage in heart transplants, shortening recovery time, and enhancing left ventricular function. BI-9740 is applicable for research related to organ transplantation.

Nafenodone is an antidepressant that decreases the frequency and amplitude of contractions while prolonging the recovery time of the sinoatrial node. In isolated rat vascular smooth muscle, Nafenodone inhibits spontaneous mechanical activity in the portal vein segments with an IC50 value of 1.4 μM. It also relaxes contractions induced by high concentrations of K+ and norepinephrine.

PI3K/mTOR-IN-20 is a selective dual inhibitor of PI3K/mTOR. It demonstrates nanomolar anti-proliferative effects in MRC-5 and Mlg2908 cells with IC50 values of 0.380 and 0.090 μM, respectively. In a Bleomycin-induced pulmonary fibrosis model, PI3K/mTOR-IN-20 reduces Ashcroft scores, decreases hydroxyproline content and collagen deposition, downregulates fibrosis-related protein expression, and aids in the repair of lung tissue structure. This compound exhibits good safety, as indicated by stable weight recovery in mice without significant hepatic or renal toxicity. PI3K/mTOR-IN-20 is useful for research on pulmonary fibroblasts.

VU0155041 sodium is a positive allosteric modulator of mGluR4, promoting extinction in male rats and inhibiting the recovery of morphine-induced conditioned place preference. It alleviates hyperalgesia in nerve injury pain models, useful in neurodegenerative disease research.

BI-9627 hydrochloride is a highly potent Na⁺/H⁺ exchanger 1 (NHE1) inhibitor. In intracellular pH recovery assays and human platelet swelling assays, its IC₅₀ values are 6 nM and 31 nM, respectively. It shows more than 30-fold selectivity over NHE2 and has no significant inhibitory effect on NHE3. BI-9627 hydrochloride can reduce the autophagy level of HTR-8/SVneo cells, significantly decrease the intracellular pH of human sperm, partially reverse the effect of DMA, and prolong the Ca²⁺ recovery time in KO hiPSC-CMs. BI-9627 hydrochloride has a low risk of drug-drug interactions, exhibits favorable pharmacokinetic properties in rats and dogs, and demonstrates potent activity in an ex vivo heart model of ischemia-reperfusion injury.

Detajmium is an anti-arrhythmia compound. It is an Na(+)-channel-blocking drug with an extremely long recovery from use-dependent sodium channel block.